Thyroglobulin and calcitonin measurements: pitfalls and future perspectives.
1/5 보강
Thyroid cancer is the most prevalent endocrine cancer, and the prognosis depends on the type and stage of cancer at the time of discovery.
APA
Mater A, Boelen A, et al. (2025). Thyroglobulin and calcitonin measurements: pitfalls and future perspectives.. The Journal of endocrinology, 264(1). https://doi.org/10.1530/JOE-24-0156
MLA
Mater A, et al.. "Thyroglobulin and calcitonin measurements: pitfalls and future perspectives.." The Journal of endocrinology, vol. 264, no. 1, 2025.
PMID
39437178 ↗
Abstract 한글 요약
Thyroid cancer is the most prevalent endocrine cancer, and the prognosis depends on the type and stage of cancer at the time of discovery. The treatment involves (hemi-)thyroidectomy, possibly followed by additional therapeutic options. After treatment, patients are monitored using serum concentrations of endocrine tumour markers: thyroglobulin (Tg) in case of differentiated cancer and calcitonin in case of medullary thyroid cancer. Measuring Tg and calcitonin concentrations in serum may be challenging. In this review, we provide a complete overview of the evolution in laboratory measurements of Tg and calcitonin, with an emphasis on (pre-)analytical challenges and potential approaches to overcome current pitfalls.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.